Amicus Therapeutics Pre-Tax Profit Margin 2007-2021 | FOLD

Amicus Therapeutics pre-tax profit margin from 2007 to 2021. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Amicus Therapeutics Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2021-09-30 $0.29B $-0.24B -79.93%
2021-06-30 $0.28B $-0.25B -88.26%
2021-03-31 $0.27B $-0.25B -93.98%
2020-12-31 $0.26B $-0.28B -105.36%
2020-09-30 $0.25B $-0.29B -118.78%
2020-06-30 $0.23B $-0.29B -127.75%
2020-03-31 $0.21B $-0.33B -155.50%
2019-12-31 $0.18B $-0.36B -195.60%
2019-09-30 $0.16B $-0.34B -214.38%
2019-06-30 $0.13B $-0.44B -333.33%
2019-03-31 $0.11B $-0.42B -382.57%
2018-12-31 $0.09B $-0.35B -378.26%
2018-09-30 $0.07B $-0.34B -460.81%
2018-06-30 $0.06B $-0.46B -715.63%
2018-03-31 $0.05B $-0.45B -890.00%
2017-12-31 $0.04B $-0.45B -1213.51%
2017-09-30 $0.03B $-0.44B -1764.00%
2017-06-30 $0.02B $-0.21B -1325.00%
2014-09-30 $0.00B $-0.06B inf%
2014-06-30 $0.00B $-0.06B inf%
2013-09-30 $0.00B $-0.06B inf%
2012-12-31 $0.02B $-0.05B -268.42%
2012-06-30 $0.03B $-0.04B -141.94%
2012-03-31 $0.02B $-0.05B -200.00%
2011-12-31 $0.02B $-0.05B -218.18%
2009-12-31 $0.06B $-0.01B -9.38%
2009-09-30 $0.02B $-0.05B -278.95%
2009-06-30 $0.02B $-0.05B -266.67%
2009-03-31 $0.02B $-0.04B -252.94%
2008-12-31 $0.02B $-0.04B -260.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.009B $0.261B
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09